tolododekin alfa Clinical Trials
2 recruitingDrug
Phase 12
Showing 1–2 of 2 trials
Recruiting
Phase 1
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorSolid Tumor+4 more
Ankyra Therapeutics, Inc97 enrolled5 locationsNCT06171750
Recruiting
Phase 1
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Ankyra Therapeutics, Inc60 enrolled5 locationsNCT07027514